---
title: "Revvity 10-Q filing delayed at SEC, B3 depositary says"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295565729.md"
description: "Revvity has flagged a delay in filing its Form 10-Q with the SEC. B3’s depositary bank for the company’s BDR program stated it will issue an update once the filing is posted. The notice was dated August 11, 2026."
datetime: "2026-08-11T17:47:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295565729.md)
  - [en](https://longbridge.com/en/news/295565729.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295565729.md)
generator: "portal-rs"
---

# Revvity 10-Q filing delayed at SEC, B3 depositary says

-   Revvity flagged a delay in filing its Form 10-Q with the SEC. \* B3’s depositary bank for the company’s BDR program said it will issue an update once the filing is posted. \* The notice was dated Aug. 11, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [RVTY.US](https://longbridge.com/en/quote/RVTY.US.md)

## Related News & Research

- [Hain Celestial 10-K filing is delayed at SEC, B3 says](https://longbridge.com/en/news/297688668.md)
- [Sharing Economy International files draft information statement with SEC](https://longbridge.com/en/news/297833109.md)
- [Regenerex Pharma delays SEC quarterly filings amid added accounting and reconciliation work](https://longbridge.com/en/news/297685504.md)
- [QXO files Form 3 for President and COO Kenneth J. West initial beneficial ownership statement](https://longbridge.com/en/news/298071722.md)
- [Acrivon Therapeutics files Form 3 for Chief Business Officer Michaela Levin](https://longbridge.com/en/news/297826865.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**